immunocore-logo-2018
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
December 02, 2022 07:30 ET | Immunocore Holdings Limited
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer potential to address large number of patients without HLA restrictions ...
immunocore-logo-2018
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc...
immunocore-logo-2018
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
November 11, 2022 09:00 ET | Immunocore Holdings Limited
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is...
immunocore-logo-2018
Immunocore to present at the Jefferies London Healthcare Conference
November 10, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR),...
immunocore-logo-2018
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity...
immunocore-logo-2018
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
September 09, 2022 10:00 ET | Immunocore Holdings Limited
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME×CD3...
immunocore-logo-2018
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
immunocore-logo-2018
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
August 03, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc...
immunocore-logo-2018
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
immunocore-logo-2018
Immunocore Announces $140 Million Private Placement Financing
July 18, 2022 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...